2021

1. Iwami D, Matsumoto T, Ono K, Hotta K, Ota M, Chiba Y, Sasaki H, Hirose T, Higuchi H, Takada Y,Iwahara N, Murai S, Shinohara N: Novel double-filtration plasmapheresis preserves fibrinogen while removing
immunoglobulin-G antibodies before ABO blood type-incompatible kidney transplantation. Renal
Replacement Therapy. 2021 7 (1): doi: https://doi.org/10.1186/s41100-021-00379-z. [5y-IF: N/A]
2. Kobayashi S, Sata F, Ikeda-Araki A, Miyashita C, Itoh S, Goudarzi H, Iwasaki Y, Mitsui T, Moriya K, Shinohara N,Cho K, Kishi R: Associations among maternal perfluoroalkyl substance levels, fetal sex-hormone enzymaticgene polymorphisms, and fetal sex hormone levels in the Hokkaido study. Reprod Toxicol. 2021 Oct; 105:221-231. [5y-IF: 3.98]
3. Kon M, Nakamura M, Moriya K, Nishimura Y, Hirata Y, Nishida M, Higuchi M, Kitta T, Shinohara N: What are
the Optimal Renal Ultrasound Parameters for Detecting Small Kidney in Young Children? Res Rep Urol.
2021 Oct; 13: 767-772. [5y-IF: N/A]
4. Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, Shinohara N: Primary renal
leiomyosarcoma with a tumor thrombus in the inferior vena cava. IJU Case Rep. 2021 Nov; 5 (1): 66-69.
[5y-IF: N/A]
5. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K,
Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: Are simple verbal instructions
sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot
scanning proton therapy? BJR Open. 2021 Nov; 3 (1): 20210064. [5y-IF: N/A]
6. Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa T, Abe T, Shinohara N:
Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary
tract urothelial carcinoma. IJU Case Rep. 2021 Dec; 5 (2): 108-112. [5y-IF: N/A]
7. Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara N, Yoshimoto T, Nakagawa Y,Fukuyama T, Oya M, Shinohara N, Uemura H, Tsuzuki T: Prognostic value of programmed death-ligand 1status in Japanese patients with renal cell carcinoma. Int J Clin Oncol. 2021 Nov; 26 (11): 2073-2084. [5yIF: 3.467]
8. Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S,
Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A,Arai Y: Health-Related Quality of Life in Testicular Cancer Survivors in Japan: A Multi-Institutional,
Cross-Sectional Study Using the EORTC QLQ-TC26. Urology. 2021 Oct; 156: 173-180. [5y-IF: 2.548]
9. Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S,
Nishimura K, Nonomura N, Kojo K, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y:
Fertility and reproductive technology use in testicular cancer survivors in Japan: A multi-institutional,
cross-sectional study. Int J Urol. 2021 Oct; 28 (10): 1047-1052. [5y-IF: 3.011]

2022
1.

Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Shinohara N: Examination ofpelvic floor muscle elasticity in patients with interstitial cystitis/bladder pain syndrome using real-timetissue elastography. Int Urogynecol J. 2022 Mar; 33 (3): 619-626. [5y-IF: 2.426]

2.

Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Shinohara N: Evaluation of pelvic
floor muscle elasticity in patients with overactive bladder syndrome using real-time tissue
elastography. Eur J Obstet Gynecol Reprod Biol. 2022 Sep; 276: 9-13. [5y-IF: 2.778]

3.

Aydın A, Ahmed K, Abe T, Raison N, Van Hemelrijck M, Garmo H, Ahmed HU, Mukhtar F, Al-Jabir A,Brunckhorst O, Shinohara N, Zhu W, Zeng G, Sfakianos JP, Gupta M, Tewari A, Gözen AS, Rassweiler J,SkolarikosA, Kunit T, Knoll T, Moltzahn F, Thalmann GN, Lantz PowersAG, Chew BH, Sarica K, Shamim KhanM, Dasgupta P SIMULATE Trial Group: Effect of Simulation-based Training on Surgical Proficiency
and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial. Eur Urol. 2022 Apr;
81 (4): 385-393. [5y-IF: 21.729]

4.

Chiba H, Kitta T, Higuchi M, Kusakabe N, Kon M, Nakamura M, Shinohara N: Ureteral reimplantation
during augmentation cystoplasty is not needed for vesicoureteral reflux in patients with neurogenic
bladder: a long-term retrospective study. BMC Urol. 2022 Mar; 22 (1): 48. [5y-IF: 2.317]

5.

Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y,Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno
A, Shinohara N: Objective evaluation of laparoscopic surgical skills in wet lab training based on motion
analysis and machine learning. Langenbecks Arch Surg. 2022 Aug; 407 (5): 2123-2132. [5y-IF: 3.116]

6.

Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto
K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao
K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N,Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M,Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N,Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N: Japan Society of Clinical Oncology Clinical
Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer
patients: part 1. Int J Clin Oncol. 2022 Feb; 27 (2): 265-280. [5y-IF: 3.467]

7.

Hayashi A, Yamamoto I, Kawabe M, Kobayashi A, Ito M, Hotta K, Shinohara N, Tasaki T, Yokoo T, Iwami
D: CASE REPORT: Serial Cases of False-Positive Flow- Cytometry T Cell Crossmatch AssociatedWith Anti-Blood Type Antibodies in Patients Undergoing ABO-Incompatible Kidney Transplantation.
Front Immunol. 2022 Mar; 13: 862652. [5y-IF: 8.876]

8.

Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N, Nounaka O, Shinno Y,Kikuchi H, Matsumoto R, Abe T, Murai S, Shinohara N: Late recurrence in patients with non-muscleinvasive bladder cancer after 5-year cancer-free periods. Int J Urol. 2022 Oct; 29 (10): 1140-1146. [5yIF: 3.011]

9.

Hirose T, Hotta K, Harada H, Tanabe T, Sasaki H, Shinohara N: Vesicoureteral reflux treatment following
kidney transplantation potentially prevents graft function deterioration and allows long-term graftsurvival. Int J Urol. 2022 Jul; 29 (7): 699-706. [5y-IF: 3.011]

10. Hirose T, Hotta K, Shinohara N: Response to Re: Vesicoureteral reflux treatment following kidneytransplantation potentially prevents graft function deterioration and allows long-term graft survival.
Int J Urol. 2022 Oct; 29 (10): 1245-1246. [5y-IF: 3.011]
11. Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, Negoro H, Mathis BJ, Maruo K, MiuraK, Sakamoto N, Shinohara N, Yamashita S, Yonemori K, Kishida T, Ukimura O, Nishimura K, Kobayashi
Y, Nishiyama H: Phase II trial of nivolumab monotherapy and biomarker screening in patients withchemo- refractory germ cell tumors. Int J Urol. 2022 Jul; 29 (7): 741-747. [5y-IF: 3.011]
12. Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro
S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S,Shinohara N: Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors inpatients with renal cell carcinoma. Urol Oncol. 2022 Jan; 40 (1): 13.e19-13.e27. [5y-IF: 3.011]
13. Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N: Outcomes of bacillus
Calmette- Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladdercancer in the second transurethral resection era. Int J Urol. 2022 Mar; 29 (3): 251-258. [5y-IF: 3.011]
14. Kitta T, Abe H, Ting-Wen H, Fujikawa M, Nakazono M, Sasa T, Doi Y, Toki S, Okada D, Ochi A, Suzuki
K, Kitagawa Y, Shinohara N: Novel insight into the correlation between hernia orifice of cystocele andlower urinary tract function: a pilot study. BMC Womens Health. 2022 May; 22 (1): 164. [5y-IF: 3.256]
15. Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, Togo M, Abe-Takahashi Y, Tsukiyama M,Shinohara N: Urodynamic evaluation of the efficacy ofvibegron, a new β3-adrenergic receptor agonist,on lower urinary tract functionin children and adolescents with overactive bladder. J Pediatr Urol.
2022 Jul; S1477-5131(22)00316-3. [5y-IF: 2.102]
16. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y,Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno
A, Shinohara N: Automatic assessment of laparoscopic surgical skill competence based on motion
metrics. PLoS One. 2022 Nov; 17 (11): e0277105. [5y-IF: 4.069]
17. Kusakabe N, Kitta T, Chiba H, Higuchi M, Shinohara N: A case of pubic osteomyelitis after
implantation of an artificial urinary sphincter: A case report. Low Urin Tract Symptoms. 2022 Jan; 14(1): 78-81. [5y-IF: N/A]
18. Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T,Tsukahara T, Kanaseki T, Shinohara N, Torigoe T: GRIK2 is a target for bladder cancer stem-like celltargeting immunotherapy. Cancer Immunol Immunother. 2022 Apr; 71 (4): 795-806. [5y-IF: 6.693]
19. Nakajima N, Miyajima A, Shinohara N, Obara W, Kondo T, Kimura G, Kume H, Fujimoto H, Sugiyama T,

Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO, Eto M: Risk factors for recurrence
after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional
national database of the Japanese Urological Association. Jpn J Clin Oncol. 2022 Mar; 52 (3): 274-280.
[5y-IF: 2.864]
20. Nishimura Y, Moriya K, Kobayashi S, Ikeda-Araki A, Sata F, Mitsui T, Itoh S, Miyashita C, Cho K, Kon M,Nakamura M, Kitta T, Murai S, Kishi R, Shinohara N: Association of exposure to prenatal perfluoroalkyl
substances and estrogen receptor 1 polymorphisms with the second to fourth digit ratio in school-aged
children: The Hokkaido study. Reprod Toxicol. 2022 Apr; 109: 10-18. [5y-IF: 3.98]

21. Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, Shinohara
N: Overview of clinical management for older patients with renal cell carcinoma. Jpn J Clin Oncol.
2022 Jul; 52 (7): 657-673. [5y-IF: 2.864]
22. Oishi Y, Kitta T, Osawa T, Abe T, Shinohara N, Nosato H, Sakanashi H, Murakawa M: Diagnosis andLocalization of Prostate Cancer via Automated Multiparametric MRI Equipped with Artificial
Intelligence. Uro. 2022 2 (1): 21-29. [5y-IF: N/A]
23. Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe A, Shinohara N:
Validation of an online application to identify potential immune-related adverse events associated withimmune checkpoint inhibitors based on the patient's symptoms. PLoS One. 2022 Mar; 17 (3): e0265230.
[5y-IF: 4.069]
24. Ouchi M, Kitta T, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, Shinohara N: Mechanisms of D1/D2like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson's
disease. Sci Rep. 2022 Mar; 12 (1): 4540. [5y-IF: 5.516]
25. Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano H, Kato T, Watari
H, Abe T, Shinohara N, Kudo K: Imaging findings of ovarian metastasis of primary renal cellcarcinoma: A case report and literature review. Radiol Case Rep. 2022 May; 17 (7): 2320-2327. [5y-IF:
N/A]
26. Tozawa A, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Harada M, Sugimoto
K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao
K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N,Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M,Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N,Yonemura M, Hayashi N, Aoki D, Suzuki N, Osuga Y: Japan Society of Clinical Oncology Clinical
Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer
patients: part 2. Int J Clin Oncol. 2022 Feb; 27 (2): 281-300. [5y-IF: 3.467]
27. Uemura H, Tomita Y, Nonomura N, Yoshizaki K, Nakao T, Shinohara N: Real-world safety andeffectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.
Int J Clin Oncol. 2022 Jun; 27 (6): 1061-1067. [5y-IF: 3.467]

28. Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N, Yoshida S, Hosoda S, Kubo
A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K,Sakamoto N: Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys fromdonorswith resolved hepatitis B virus infection. J Viral Hepat. 2022 Aug; doi:10.1111/jvh.13740. [5y-IF:3.430]
29. Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K, Morita K, Tsuchiya K,Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono T, Mochizuki T, Akino T, Sasaki Y,Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: Comparative study of
postoperative complications after radical cystectomy during the past two decades in Japan: Radicalcystectomy remains associated with significant postoperative morbidities. Urol Oncol. 2022 Jan; 40 (1):11.e17-11.e25. [5y-IF: 3.099]
30. Yamagata Y, Abe T, IwaharaN, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R,Osawa T, Shinohara N: Metastatic neuroendocrine carcinoma of right adrenal glandsuccessfully treatedwith laparoscopic adrenalectomy aftermultimodal therapy. IJU case reports. 2022 July; doi: https://doi.
org/10.1002/iju5.12511. [5y-IF: N/A]
31. Yamamoto S, Noguchi H, Takeda A, Arakaki R, Uchishiba M, Imaizumi J, Minato S, Kamada S, Kagawa T,Yoshida A, Kawakita T, Yamamoto Y, Yoshida K, Kon M, Shinohara N, Iwasa T: Changes in Endogenous
Oxytocin Levels and the Effects of Exogenous Oxytocin Administration on Body Weight Changes andFood Intake in Polycystic Ovary Syndrome Model Rats. Int J Mol Sci. 2022 Jul; 23 (15): 8207. [5y-IF:6.628]